Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Finlay

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Bioorganic & Medicinal Chemistry|May 20, 2021
Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybridsThuy Nguyen, Thomas F Gamage, Ann M Decker, et al.
Pharmacology, Biochemistry, and Behavior|February 22, 2023
The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolismDavid B Finlay, Warwick Mackie, Hunter D J Webb, et al.
Journal of Medicinal Chemistry|December 20, 2021
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking BehaviorThuy Nguyen, Thomas F Gamage, David B Finlay, et al.
Pharmacology Research & Perspectives|January 18, 2022
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018David B Finlay, Thuy Nguyen, Thomas F Gamage, et al.
Pharmacology, Biochemistry, and Behavior|April 6, 2020
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018Thomas F Gamage, Daniel G Barrus, Richard C Kevin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 9, 2020
A novel allosteric modulator of the cannabinoid CB<sub>1</sub> receptor ameliorates hyperdopaminergia endophenotypes in rodent modelsCatharine A Mielnik, Kim S Sugamori, David B Finlay, et al.
Nature Medicine|June 8, 2023
Signaling-specific inhibition of the CB<sub>1</sub> receptor for cannabis use disorder: phase 1 and phase 2a randomized trialsMargaret Haney, Monique Vallée, Sandy Fabre, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Bioorganic & Medicinal Chemistry|May 20, 2021
Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybridsThuy Nguyen, Thomas F Gamage, Ann M Decker, et al.
Pharmacology, Biochemistry, and Behavior|February 22, 2023
The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolismDavid B Finlay, Warwick Mackie, Hunter D J Webb, et al.
Journal of Medicinal Chemistry|December 20, 2021
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking BehaviorThuy Nguyen, Thomas F Gamage, David B Finlay, et al.
Pharmacology Research & Perspectives|January 18, 2022
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018David B Finlay, Thuy Nguyen, Thomas F Gamage, et al.
Pharmacology, Biochemistry, and Behavior|April 6, 2020
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018Thomas F Gamage, Daniel G Barrus, Richard C Kevin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 9, 2020
A novel allosteric modulator of the cannabinoid CB<sub>1</sub> receptor ameliorates hyperdopaminergia endophenotypes in rodent modelsCatharine A Mielnik, Kim S Sugamori, David B Finlay, et al.
Nature Medicine|June 8, 2023
Signaling-specific inhibition of the CB<sub>1</sub> receptor for cannabis use disorder: phase 1 and phase 2a randomized trialsMargaret Haney, Monique Vallée, Sandy Fabre, et al.
Pageof 4